Article

Pharma USA 2023: Digital Therapeutics and Pharma

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

Tracey Dodenhoff, CEO of Medly Therapeutics, discusses her company's heart failure app and why pharma should consider prescription digital therapeutics among their offerings.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Joel Stanley
August 1st 2025

How the Entourage Effect Is Reshaping Botanical Drug Development

Joel Stanley
In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 1st 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Credit: rudall30 | stock.adobe.com. Hands offering money with a circular chart at the center, symbolizing shareholder equity, crowdfunding, business partnerships, and investments
August 1st 2025

Capital Allocation is Strategy: Five Imperatives for Biopharma Leaders

Thani Jambulingam, PhD
Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.